Rizatriptan orally-dissolving film - NAL Pharma

Drug Profile

Rizatriptan orally-dissolving film - NAL Pharma

Alternative Names: NAL-1606; Rizatriptan benzoate - NAL Pharma; Rizatriptan ODF

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator NAL Pharma
  • Class Antimigraines; Small molecules; Triazoles; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Migraine

Highest Development Phases

  • Clinical Phase Unknown Migraine

Most Recent Events

  • 28 Apr 2016 Chemical structure information added
  • 21 Apr 2016 Rizatriptan orally-dissolving film - NAL Pharma is available for licensing in World as of 21 Apr 2016. http://www.nalpharma.com/
  • 21 Apr 2016 Clinical trials in Migraine in Hong Kong (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top